Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bamlanivimab + etesevimab + bebtelovimab
- Development stage
- Preclinical
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination drug consisting of three monoclonal antibodies—**bamlanivimab**, **etesevimab**, and **bebtelovimab**—designed for the treatment of mild to moderate COVID-19. All three components are neutralizing IgG1κ monoclonal antibodies that target distinct epitopes on the surface spike protein of SARS-CoV-2. By binding to the spike protein, they inhibit viral attachment and entry into human cells, thereby reducing viral replication and disease progression. These antibodies were originally developed as separate agents with demonstrated activity against various SARS-CoV-2 variants. The triple combination is intended to enhance antiviral efficacy and reduce the risk of viral escape mutants.
- Other names
- bamlanivimab and etesevimab and bebtelovimab combination
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)Omicron RBD (SARS-CoV-2 Omicron spike receptor-binding domain)
Beyond the preview
Go deeper on bamlanivimab + etesevimab + bebtelovimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bamlanivimab + etesevimab + bebtelovimab.